Cargando…
Survival and clinicopathological significance of PYCR1 expression in cancer: A meta-analysis
BACKGROUND: Proline metabolism is closely related to the occurrence and development of cancer. Δ1-Pyrroline-5-carboxylate reductase (PYCR) is the last enzyme in proline biosynthesis. As one of the enzyme types, PYCR1 takes part in the whole process of the growth, invasion, and drug resistance of can...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480090/ https://www.ncbi.nlm.nih.gov/pubmed/36119513 http://dx.doi.org/10.3389/fonc.2022.985613 |
_version_ | 1784790968227069952 |
---|---|
author | Li, Yue Xu, Jiahuan Bao, Pengchen Wei, Zhijing Pan, Lei Zhou, Jiawei Wang, Wei |
author_facet | Li, Yue Xu, Jiahuan Bao, Pengchen Wei, Zhijing Pan, Lei Zhou, Jiawei Wang, Wei |
author_sort | Li, Yue |
collection | PubMed |
description | BACKGROUND: Proline metabolism is closely related to the occurrence and development of cancer. Δ1-Pyrroline-5-carboxylate reductase (PYCR) is the last enzyme in proline biosynthesis. As one of the enzyme types, PYCR1 takes part in the whole process of the growth, invasion, and drug resistance of cancer cells. This study investigated PYCR1 expressions in cancers together with their relationship to clinical prognosis. METHODS: A thorough database search was performed in PubMed, EMBASE, and Cochrane Library. RevMan5.3 software was used for the statistical analysis. RESULTS: Eight articles were selected, and 728 cancer patients were enrolled. The cancer types include lung, stomach, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, and renal cell carcinoma. The meta-analysis results showed that the expression of PYCR1 was higher in the clinical stage III–IV group than that in the clinical stage I–II group (OR = 1.67, 95%CI: 1.03–2.71), higher in the lymph node metastasis group than in the non-lymph node metastasis group (OR = 1.57, 95%CI: 1.06–2.33), and higher in the distant metastasis group than in the non-distant metastasis group (OR = 3.46, 95%CI: 1.64–7.29). However, there was no statistical difference in PYCR1 expression between different tumor sizes (OR = 1.50, 95%CI: 0.89–2.53) and degrees of differentiation (OR = 0.82, 95%CI: 0.54–1.24). CONCLUSION: PYCR1 had a high expression in various cancers and was associated with cancer volume and metastasis. The higher the PYCR1 expression was, the poorer the cancer prognosis was. The molecular events and biological processes mediated by PYCR1 might be the underlying mechanisms of metastasis. |
format | Online Article Text |
id | pubmed-9480090 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94800902022-09-17 Survival and clinicopathological significance of PYCR1 expression in cancer: A meta-analysis Li, Yue Xu, Jiahuan Bao, Pengchen Wei, Zhijing Pan, Lei Zhou, Jiawei Wang, Wei Front Oncol Oncology BACKGROUND: Proline metabolism is closely related to the occurrence and development of cancer. Δ1-Pyrroline-5-carboxylate reductase (PYCR) is the last enzyme in proline biosynthesis. As one of the enzyme types, PYCR1 takes part in the whole process of the growth, invasion, and drug resistance of cancer cells. This study investigated PYCR1 expressions in cancers together with their relationship to clinical prognosis. METHODS: A thorough database search was performed in PubMed, EMBASE, and Cochrane Library. RevMan5.3 software was used for the statistical analysis. RESULTS: Eight articles were selected, and 728 cancer patients were enrolled. The cancer types include lung, stomach, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, and renal cell carcinoma. The meta-analysis results showed that the expression of PYCR1 was higher in the clinical stage III–IV group than that in the clinical stage I–II group (OR = 1.67, 95%CI: 1.03–2.71), higher in the lymph node metastasis group than in the non-lymph node metastasis group (OR = 1.57, 95%CI: 1.06–2.33), and higher in the distant metastasis group than in the non-distant metastasis group (OR = 3.46, 95%CI: 1.64–7.29). However, there was no statistical difference in PYCR1 expression between different tumor sizes (OR = 1.50, 95%CI: 0.89–2.53) and degrees of differentiation (OR = 0.82, 95%CI: 0.54–1.24). CONCLUSION: PYCR1 had a high expression in various cancers and was associated with cancer volume and metastasis. The higher the PYCR1 expression was, the poorer the cancer prognosis was. The molecular events and biological processes mediated by PYCR1 might be the underlying mechanisms of metastasis. Frontiers Media S.A. 2022-09-02 /pmc/articles/PMC9480090/ /pubmed/36119513 http://dx.doi.org/10.3389/fonc.2022.985613 Text en Copyright © 2022 Li, Xu, Bao, Wei, Pan, Zhou and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Li, Yue Xu, Jiahuan Bao, Pengchen Wei, Zhijing Pan, Lei Zhou, Jiawei Wang, Wei Survival and clinicopathological significance of PYCR1 expression in cancer: A meta-analysis |
title | Survival and clinicopathological significance of PYCR1 expression in cancer: A meta-analysis |
title_full | Survival and clinicopathological significance of PYCR1 expression in cancer: A meta-analysis |
title_fullStr | Survival and clinicopathological significance of PYCR1 expression in cancer: A meta-analysis |
title_full_unstemmed | Survival and clinicopathological significance of PYCR1 expression in cancer: A meta-analysis |
title_short | Survival and clinicopathological significance of PYCR1 expression in cancer: A meta-analysis |
title_sort | survival and clinicopathological significance of pycr1 expression in cancer: a meta-analysis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480090/ https://www.ncbi.nlm.nih.gov/pubmed/36119513 http://dx.doi.org/10.3389/fonc.2022.985613 |
work_keys_str_mv | AT liyue survivalandclinicopathologicalsignificanceofpycr1expressionincancerametaanalysis AT xujiahuan survivalandclinicopathologicalsignificanceofpycr1expressionincancerametaanalysis AT baopengchen survivalandclinicopathologicalsignificanceofpycr1expressionincancerametaanalysis AT weizhijing survivalandclinicopathologicalsignificanceofpycr1expressionincancerametaanalysis AT panlei survivalandclinicopathologicalsignificanceofpycr1expressionincancerametaanalysis AT zhoujiawei survivalandclinicopathologicalsignificanceofpycr1expressionincancerametaanalysis AT wangwei survivalandclinicopathologicalsignificanceofpycr1expressionincancerametaanalysis |